Miniatura

Fitxers

agrawal-et-al-2025-transcriptomic-predictors-of-survival-for-palbociclib-endocrine-therapy-versus-capecitabine-in.pdf (1.24 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-07-01

Llicència de publicació

cc by-nc-nd (c) Agrawal, Yash N. et al, 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/222811

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1200/PO-24-00937

Resum

PURPOSEFor hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC), first-line cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) + endocrine therapy (ET) is the standard of care. They are also used after progression on first-line aromatase inhibitors (AIs), but some patients may respond better to chemotherapy-based options. We examined tumor features associated with survival from GEICAM/2013-02 PEARL, a phase III trial of palbociclib + ET versus capecitabine in AI-resistant HR+/HER2- MBC.METHODSFor 158 and 155 patients from each arm, 878 previously published gene expression signatures were derived using RNA sequencing on pretreatment tumor specimens, both primary and metastatic. Multivariable Cox models for progression-free survival (PFS) and overall survival (OS) were constructed with 16 preselected signatures related to proliferation, loss of retinoblastoma, and immune infiltration, and via Elastic Net using all signatures.RESULTSSignificant PFS difference by PAM50 intrinsic subtype was observed with palbociclib + ET. Comparing treatment arms, luminal A subtype trended toward longer PFS with palbociclib + ET, and luminal B and nonluminal subtypes had significantly longer PFS with capecitabine. Three B-cell (B-lymphocyte)-associated signatures correlated with shorter OS with palbociclib + ET. The immune-activated Immune1 TCGA breast cancer signature had significant treatment arm interaction for OS. Elastic Net iteratively selected B-cell-associated signatures independently associated with shorter OS with palbociclib + ET.CONCLUSIONPAM50 intrinsic subtype predicted PFS differences between palbociclib + ET and capecitabine. Lower B-cell-associated gene expression predicted longer OS with palbociclib + ET versus capecitabine. These features may help identify HR+/HER2- tumors resistant to further ET-based treatment with CDK4/6i.

Matèries

Càncer de mama, Tractament adjuvant del càncer

Matèries (anglès)

Breast cancer

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

AGRAWAL, Yash n., FERNÁNDEZ MARTÍNEZ, Aranzazu, GIL GIL, Miguel, ZIELINSKI, Christoph, RUIZ BORREGO, Manuel, CIRUELOS, Eva, MUÑOZ MATEU, Montserrat, MARGELÍ VILA, Mireia, BERMEJO DE LAS HERAS, Begoña, ANTON TORRES, Antonio, KAHAN, Zsuzsanna, CSÖSZI, Tibor, ALONSO ROMERO, José luis, GARCÍA SAENZ, José ángel, SÁNCHEZ ROVIRA, Pedro, ÁLVAREZ, Elena, CHACÓN, José ignacio, GONZÁLEZ SANTIAGO, Santiago, RODRÍGUEZ SÁNCHEZ, César a., SERVITJA, Sonia, PFEFFERLE, Adam d., HERRANZ, Jesús, LIU, Yuan, CAREY, Lisa a., ROMERO CAMARERO, Isabel, CABALLERO, Rosalía, GUERRERO ZOTANO, Ángel, PEROU, Charles m., MARTÍN, Miguel. Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial. _JCO Precision Oncology_. 2025. Vol. 9. [consulta: 23 de gener de 2026]. ISSN: 2473-4284. [Disponible a: https://hdl.handle.net/2445/222811]

Exportar metadades

JSON - METS

Compartir registre